about
Overexpression of angiopoietin-like protein 4 protects against atherosclerosis developmentPioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetesGLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden miceAcute central neuropeptide Y administration increases food intake but does not affect hepatic very low-density lipoprotein (VLDL) production in miceBoth transient and continuous corticosterone excess inhibit atherosclerotic plaque formation in APOE*3-leiden.CETP miceBMP7 activates brown adipose tissue and reduces diet-induced obesity only at subthermoneutrality.CETP expression reverses the reconstituted HDL-induced increase in VLDL.Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol efflux properties of HDLAnacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.Serum CETP concentration is not associated with measures of body fat: The NEO study.Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in miceShort-term high-fat diet increases macrophage markers in skeletal muscle accompanied by impaired insulin signalling in healthy male subjects.Male apoE*3-Leiden.CETP mice on high-fat high-cholesterol diet exhibit a biphasic dyslipidemic response, mimicking the changes in plasma lipids observed through life in men.Differential complement activation pathways promote C3b deposition on native and acetylated LDL thereby inducing lipoprotein binding to the complement receptor 1.Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice.The aminoterminal 1-185 domain of human apolipoprotein E suffices for the de novo biogenesis of apoE-containing HDL-like particles in apoA-I deficient mice.Overexpression of apolipoprotein AV in the liver reduces plasma triglyceride and cholesterol but not HDL in ApoE deficient mice.Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels.Enhanced atherothrombotic formation after oxidative injury by FeCl3 to the common carotid artery in severe combined hyperlipidemic mice.Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit.Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.Lipopolysaccharide Lowers Cholesteryl Ester Transfer Protein by Activating F4/80+Clec4f+Vsig4+Ly6C- Kupffer Cell Subsets.Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells.Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice.Impact of rural-urban environment on metabolic profile and response to a 5-day high-fat diet.In vivo and in silico dynamics of the development of Metabolic Syndrome.Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in SepsisComputational modelling of energy balance in individuals with Metabolic SyndromeCETP (Cholesteryl Ester Transfer Protein) Concentration: A Genome-Wide Association Study Followed by Mendelian Randomization on Coronary Artery DiseaseMetabolic liver inflammation in obesity does not robustly decrease hepatic and circulating CETPA Novel Role for CETP as Immunological Gatekeeper: Raising HDL to Cure Sepsis?Diabetic Nephropathy Alters the Distribution of Circulating Angiogenic MicroRNAs Among Extracellular Vesicles, HDL, and Ago-2Inhibition of Δ24-dehydrocholesterol reductase activates pro-resolving lipid mediator biosynthesis and inflammation resolutionColesevelam enhances the beneficial effects of brown fat activation on hyperlipidemia and atherosclerosis developmentHepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohortMendelian randomization reveals unexpected effects of CETP on the lipoprotein profile
P50
Q28290052-949C0EA4-EBB0-49E0-B366-A3AB07C94697Q33932844-F7702E68-C514-47AE-8222-369F8AC84584Q34469947-27F7CB81-8792-4A6B-8B53-E1B4A1C50A38Q34608233-91E09EFF-0709-4CE4-89D9-C6198689382CQ34744777-036C00F0-F369-4271-9E0D-3A60F6CB1A6FQ34997193-F24EB307-1270-484F-B0D4-2433A5E9A175Q35107299-1D8D93EB-C597-4455-AFEF-6E3F882FF3A2Q35563676-613EAC9A-EFB1-4A45-9B96-7D41BF9330D6Q36197815-1CCEA645-E47D-4832-BDEF-3C93A16D2559Q37671303-560F96AD-AF3B-4DAF-A7AE-83233725530FQ40945215-B91CB911-68B7-49F6-8E63-A97B2B7F1A78Q41553213-1BEF46AF-AC94-47D3-AF2F-7E4F2BE3ABB4Q42200706-8ACDA655-BD9B-4988-89C2-2282B7F417F9Q42378083-4433D96B-5409-4B8B-A76A-DB67800C7703Q42538288-1F0E8B92-D6D6-40A9-B1C8-21E2741578CAQ42713323-544074D9-D6F7-4FFE-89F8-D2D6611F9A68Q43199097-E8E1C63F-7E7D-40AD-A137-5674CE62769DQ43740803-22E24C4B-A17E-48E3-9D1D-77B9C42A630FQ45266349-2DBB8D9F-3683-404B-A51B-3E23D44CD9ADQ46897547-1C6C26E2-76B5-4C51-8F72-9F174F5EBB05Q47691945-875CB26A-1E5A-4712-95B7-D05F6B16EDAEQ47987772-7866D074-FD60-4B43-9B1C-12E1F3346E91Q50091202-813B6B7F-E478-41EC-918F-A4A96B38F6A9Q51741688-BA50ACDF-B008-42A0-88C2-190F35AAD360Q52931087-E136080D-5D6A-4B39-AB5F-F9EAA775A743Q53159775-972A0BA0-DF94-459B-BABA-AFCCFFA35A4CQ55004544-3586FAF6-8D5D-4B27-9A26-ECFC32AF80E0Q55166354-1BCF0A37-7D5B-4314-9724-295E8AE4A081Q57461015-45155F22-F681-4ED2-90F9-0546F7E3DA8DQ64099419-5A4ABC30-A037-4883-B566-D1ECDC22BB69Q88573539-1689D66D-585B-41E8-AF60-94AC945547EAQ89104897-7A5A1A51-3723-4976-BA04-F3FD3AD75472Q89600581-A6FB8F5F-B7F8-4DA4-9F6D-AFDB1483C4C8Q90044094-053341A8-4DF7-460A-B795-A295F44EB7ADQ90240416-83F756FB-514F-47F7-BE1E-005E030091DCQ90557580-5D4077E9-BB32-42E6-9B1D-71D84CEF60A0Q91776561-C9B40F10-8347-4307-B758-E9FFBAD505B9Q93017355-A874C5DA-066E-490F-BDE8-3643D63F38B1
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yanan Wang
@ast
Yanan Wang
@en
Yanan Wang
@es
Yanan Wang
@nl
type
label
Yanan Wang
@ast
Yanan Wang
@en
Yanan Wang
@es
Yanan Wang
@nl
prefLabel
Yanan Wang
@ast
Yanan Wang
@en
Yanan Wang
@es
Yanan Wang
@nl
P106
P21
P31
P496
0000-0002-0327-0458